"The U.S. Food and Drug Administration today approved Tivicay (dolutegravir), a new drug to treat HIV-1 infection.
Tivicay is an integrase strand transfer inhibitor that interferes with one of the enzymes necessary for HIV to multiply. "...
There have been more than 60 reports of acute or chronic human overdosage (up to 23 times the recommended total daily dose of 2400 mg) with CRIXIVAN. The most commonly reported symptoms were renal (e.g., nephrolithiasis/urolithiasis, flank pain, hematuria) and gastrointestinal (e.g., nausea, vomiting, diarrhea).
CRIXIVAN is contraindicated in patients with clinically significant hypersensitivity to any of its components.
Inhibition of CYP3A4 by CRIXIVAN can result in elevated plasma concentrations of the following drugs, potentially causing serious or life-threatening reactions:
Table 7: Drug Interactions
With Crixivan: Contraindicated Drugs
|Drug Class||Drugs Within Class That Are Contraindicated With CRIXIVAN|
|Alpha 1-adrenoreceptor antagonist||alfuzosin|
|Ergot derivatives||dihydroergotamine, ergonovine, ergotamine, methylergonovine|
|GI motility agents||cisapride|
|HMG-CoA Reductase Inhibitors||lovastatin, simvastatin|
|PDE5 Inhibitors||Revatio (sildenafil) [for treatment of pulmonary arterial hypertension]|
|Sedative/hypnotics||oral midazolam, triazolam, alprazolam|
|* Registered trademark of Pfizer, Inc.|
Last reviewed on RxList: 8/7/2014
This monograph has been modified to include the generic and brand name in many instances.
Additional Crixivan Information
Crixivan - User Reviews
Crixivan User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get breaking medical news.